Transdermal Estradiol/Norethisterone

@article{Wiseman1994TransdermalE,
  title={Transdermal Estradiol/Norethisterone},
  author={Lynda R. Wiseman and Donna McTavish},
  journal={Drugs \& Aging},
  year={1994},
  volume={4},
  pages={238-256}
}
SummarySynopsisThe combined transdermal estradiol/norethisterone therapeutic system is designed to deliver both estradiol and norethisterone into the systemic circulation at a constant rate for up to 4 days when affixed to the skin. Transdermal administration avoids hepatic first- pass metabolism, allowing therapeutic concentrations of the progestogen and estrogen to be maintained in postmenopausal women following low dose administration. Transdermal norethisterone does not appear to alter the… Expand
Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
TLDR
A continuous combined low-dose transdermal patch daily delivering 0.025 mg estradiol and 0.125 mg norethisterone acetate provided beneficial effects on lipid/lipoprotein profile and coagulation/fibrinolysis, similar to those previously described after higher dose oral and transderal estrogen/progestogen regimens. Expand
The influence of transdermal oestradiol replacement therapy and medroxyprogesterone acetate on serum lipids and lipoproteins.
TLDR
Transdermal oestrogen therapy appears to be of particular benefit for women with hypertriglyceridaemia and there were no significant adverse effects of medroxyprogesterone acetate on serum lipids and lipoproteins. Expand
Safety and efficacy of transdermal estradiol replacement therapy in postmenopausal liver transplanted women
TLDR
Estrogen replacement therapy did not impair any of the liver parameters measured and no thrombotic effect could be detected, and Liver function and hemostatic balance were unaffected by the transdermal hormonal treatment. Expand
The influence of medroxyprogesterone acetate on the effects of transdermal oestradiol replacement therapy on plasma lipids.
TLDR
Transdermal oestradiol may be of particular clinical benefit for women with hypertriglyceridaemia and medroxyprogesterone acetate did not exert a significantly adverse influence on plasma lipid and lipoprotein concentrations. Expand
Efficacy and tolerability of fully transdermal hormone replacement in sequential or continuous therapy at two doses of progestogen in postmenopausal women.
TLDR
Fully transdermal sequential or continuous HRT is effective and well tolerated in postmenopausal women and the lower doses of NETA may be preferable, because it confers adequate endometrial protection at a lower dose of progestogen. Expand
Effect of an estradiol gel with monthly or quarterly progestogen on menopausal symptoms and bleeding
TLDR
Both the 1- and 3-month regimens were equally effective in controlling climacteric symptoms and protecting against endometrial hyperstimulation and Estradiol gel was highly acceptable to the majority of women. Expand
Pharmacology of estrogens and progestogens: influence of different routes of administration
  • H. Kuhl
  • Medicine
  • Climacteric : the journal of the International Menopause Society
  • 2005
This review comprises the pharmacokinetics and pharmacodynamics of natural and synthetic estrogens and progestogens used in contraception and therapy, with special consideration of hormoneExpand
An initial pharmacokinetic study with a Metered Dose Transdermal Systemfor delivery of the progestogen Nestorone as a possible future contraceptive.
TLDR
This early pharmacokinetic trial of a new transdermal steroid delivery system has demonstrated the feasibility of achieving serum levels of NES sufficient to block ovulation and potentially provide effective contraception. Expand
Evaluation of the bioavailability and dose proportionality of three formulations of a combination estrogen and progestin adhesive-based matrix transdermal delivery system
Abstract The single-dose and steady-state pharmacokinetics of estradiol (E 2 ), estrone, and norethindrone acetate (NETA) were examined in three studies of healthy postmenopausal women afterExpand
A current perspective into young female sex hormone replacement: a review
TLDR
Evidence suggests that micronized progesterone may be associated with fewer side effects, although its effect on endometrial protection is not yet proven, and synthetic progestins confer varying degrees of androgenic and thromboembolic properties which should be kept in mind when prescribing individualized treatment. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 75 REFERENCES
Transdermal Estradiol
TLDR
Available evidence suggests that transdermal estradiol may represent an attractive alternative to other forms of estrogen therapy for the prevention, and possibly treatment, of postmenopausal osteoporosis. Expand
Transdermal administration of oestrogen/progestagen hormone replacement therapy
TLDR
Preliminary findings show that transdermal progestagen can be successfully administered in hormone replacement therapy to prevent endometrial proliferation while minimising the adverse effects that may be seen with oral administration. Expand
Endometrial effects of transdermal estradiol/norethisterone acetate.
TLDR
Vaginal cytology showed a significant shift towards increased maturation during treatment with transdermal norethisterone acetate, and the incidence of endometrial hyperplasia and the effects on the vaginal cytology were determined. Expand
Comparison of transdermal and oral estrogen-progestin replacement therapy: effects on serum lipids and lipoproteins.
TLDR
Transdermal and oral therapies had similar effects on lipoprotein cholesterol but different effects on triglycerides, and oral therapy increased triglycerides whereas this lipid fell with transdermal therapy. Expand
A Risk-Benefit Appraisal of Transdermal Estradiol Therapy
TLDR
Transdermal administration of estradiol appears to be at least as effective as oral conjugated estrogen therapy on most of the end-points which have been evaluated, but allows a lower dose to be used, avoiding some of the metabolic adverse effects experienced with oral treatment. Expand
Plasma lipid and lipoprotein effects of transdermal administration of estradiol and estradiol/norethisterone acetate.
TLDR
The present study by transdermal sequential hormonal treatment results in a lipid and lipoprotein pattern with reduced total cholesterol and LDL cholesterol in postmenopausal women. Expand
A transdermal regimen for continuous combined hormone replacement therapy in the menopause.
TLDR
A skin patch releasing 0.05 mg oestradiol and 0.25 mg norethisterone acetate per day was used in a continuous manner for oestrogen therapy in the menopause and results were quite favourable. Expand
Does low-dose, transdermal, norethisterone acetate reliably cause endometrial transformation in postmenopausal oestrogen-users?
TLDR
This dose of transdermal norethisterone acetate is regarded as inadequate in combination withtransdermal oestradiol 50 micrograms/day for routine use in postmenopausal oestrogen users. Expand
Estrogen replacement therapy by transdermal estradiol administration.
TLDR
The results indicate that transdermal E2 administration may be used to provide estrogen replacement while exerting limited effects on hepatic function, and variable responses of the different biochemical and biologic markers of the actions of E2 were observed. Expand
Long-Term Transdermal Estradiol Therapy: Effects on Endometrial Histology and Bleeding Patterns
TLDR
The data suggest that transdermal E2 is safe with respect to endometrial histology if administered with a cyclic progestin. Expand
...
1
2
3
4
5
...